Therapeutic Workshop
Diabetes Enters A New Decade: Is It Really Out with the Old and In with the New?
Wednesday, October 19
9:10 a.m. - 10:10 a.m.
Sea Cliff
Emerging therapies to treat diabetes are raising hopes for better options for managing this disease, and clinical advances are making this possibility a near-term reality. One class of new drugs, known as glucagon-like peptide 1 (GLP-1), acts to stimulate the release of insulin from pancreatic beta cells and has a product recently launched on the market. Two other new classes of drugs are also under development, DPP-IV (dipeptidyl peptidase IV) inhibitors work to stop degradation of natural GLP-1 in the body and new dual PPAR inhibitors work not only to sensitize insulin but also decrease triglycerides without traditional weight gain associated with TZDs. Industry and clinical experts discussed the latest developments in these two new classes of therapies, focusing on their merits and limitations as well their potential benefits over traditional disease management approaches.
Moderator:
- Lei Zhong, PhD, Senior Analyst, Bank of America Securities LLC
Panelists:
- Linda A. Egger, PhD, Senior Scientist, Scientific Licensing, External Scientific Affairs, Merck & Co., Inc.
- Fred Levine, MD, PhD, Associate Professor of Pediatrics, Center for Molecular Genetics, UCSD School of Medicine
- Harold Van Wart, PhD, President, CEO and Director, Metabolex, Inc.